We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis.
- Authors
Umemura, Takeji; Sekiguchi, Tomohiro; Joshita, Satoru; Yamazaki, Tomoo; Fujimori, Naoyuki; Shibata, Soichiro; Ichikawa, Yuki; Komatsu, Michiharu; Matsumoto, Akihiro; Shums, Zakera; Norman, Gary L.; Tanaka, Eiji; Ota, Masao
- Abstract
Background & Aims Primary biliary cholangitis ( PBC) is an autoimmune liver disease characterized by portal inflammation and immune-mediated destruction of intrahepatic bile ducts that often leads to liver decompensation and liver failure. Although the biochemical response to ursodeoxycholic acid ( UDCA) can predict disease outcome in PBC, few biomarkers have been identified as prognostic tools applicable prior to UDCA treatment. We therefore sought to identify such indicators of long-term outcome in PBC in the Japanese population. Methods The prebiopsy serum samples and subsequent clinical data of 136 patients with PBC treated with UDCA were analysed over a median follow-up period of 8.8 years. Serum levels of biomarkers related to microbial translocation ( sCD14, Endo CAb and I- FABP) were measured along with those of 33 cytokines and chemokines and additional auto-antibodies. Associations between the tested parameters and the clinical outcomes of liver decompensation and liver-related death/liver transplantation were evaluated using the Cox proportional hazards model with stepwise methods and Kaplan-Meier analysis. Results Elevated levels of serum IL-8, and sCD14 before UDCA therapy were significantly associated with both liver decompensation and liver-related death/liver transplantation. In multivariate analyses, IL-8≥46.5 pg/ mL or sCD14≥2.0 μg/ mL at enrolment demonstrated the same results. Kaplan-Meier analysis also revealed IL-8 and sCD14 to be significantly associated with a poor outcome. sCD14 was significantly correlated with IL-8. Endo CAb and I- FABP were not related to disease outcome. Conclusions Serum IL-8 and sCD14 levels before UDCA therapy represent noninvasive surrogate markers of prognosis in patients with PBC.
- Subjects
CHOLANGITIS; LIVER diseases; LIVER disease treatment; BILE duct diseases; LIVER degeneration; PATIENTS; THERAPEUTICS
- Publication
Liver International, 2017, Vol 37, Issue 6, p897
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.13316